Biocon makes Biocon Biologics a wholly-owned subsidiary via share swap

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.1%Reaction day

₹414.20

prior close

₹416.15

announcement price

After-mkt

timing

Nifty Midcap 150market+0.4%+0.7% vs market

Pharmaceuticals peers, median of 165sector+0.8%+0.3% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty Midcap 150 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-0.8

15m

-0.7

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.1+0.4+0.7+0.8+0.3

Next day

+0.9+0.6+0.3+0.3+0.6

+1.2+1.1+0.1+0.8+0.4

+3.3+0.9+2.4+1.2+2.1

+2.4+1.3+1.1+0.6+1.7

-2.0+1.0-3.0+0.2-2.2

-1.9+0.8-2.6+0.7-2.5

15d

+6.4+2.2+4.2+1.7+4.6

+2.8+1.6+1.3-0.5+3.4

-0.5+3.8-4.3+3.0-3.5

-10.6-3.6-7.0+3.3-13.9

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon completed acquisition of 1,15,36,956 equity shares of its material subsidiary Biocon Biologics (BBL) from 127 selling shareholders, making BBL a wholly-owned subsidiary from June 29, 2026. As consideration, Biocon allotted 87,86,362 new equity shares at Rs. 376.41 each on a preferential basis. Share capital rose to Rs. 814.85 crore from Rs. 810.45 crore. Postal ballot approval received on June 7, 2026.

Likely market impact

Slight dilution for existing Biocon shareholders; full ownership of biologics arm, may support future value unlocking or potential listing.